The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
A comprehensive insight on ocular pharmacokinetics
Open accessAbstract
The eye is a distinctive organ with protective anatomy and physiology. Several pharmacokinetics compartment models of ocular drug delivery have been developed for describing the absorption, distribution, and elimination of ocular drugs in the eye. Determining pharmacokinetics parameters in ocular tissues is a major challenge because of the complex anatomy and dynamic physiological barrier of the eye. In this review, pharmacokinetics of these compartments exploring different drugs, delivery systems, and routes of administration is discussed including factors affecting intraocular bioavailability. Factors such as precorneal fluid drainage, drug binding to tear proteins, systemic drug absorption, corneal factors, melanin binding, and drug metabolism render ocular delivery challenging and are elaborated in this manuscript. Several compartment models are discussed; these are developed in ocular drug delivery to study the pharmacokinetics parameters. There are several transporters present in both anterior and posterior segments of the eye which play a significant role in ocular pharmacokinetics and are summarized briefly. Moreover, several ocular pharmacokinetics animal models and relevant studies are reviewed and discussed in addition to the pharmacokinetics of various ocular formulations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
Gaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406
Self-citationChallenges and obstacles of ocular pharmacokinetics and drug delivery
Urtti, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.027 · Cited by 1,003
Ocular drug delivery systems: An overview
Patel, A. (2013) · World Journal of Pharmacology · doi:10.5497/wjp.v2.i2.47 · Cited by 890
Pharmacokinetics of Intravitreal Bevacizumab (Avastin)
Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., & Singh, R. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.01.017 · Cited by 683
Recent Perspectives in Ocular Drug Delivery
Gaudana, R., Jwala, J., Boddu, S. H. S., & Mitra, A. K. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9694-0 · Cited by 605
Self-citationPharmacokinetics and Pharmacodynamics of Antibacterial Agents
Levison, M. E., & Levison, J. H. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.06.008 · Cited by 557
Pharmacokinetics of Intravitreal Ranibizumab (Lucentis)
Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., Ezzat, M. K., & Singh, R. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.09.012 · Cited by 541
Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration
Gaudreault, J., Fei, D., Rusit, J., Suboc, P., & Shiu, V. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0601 · Cited by 501
Human Corneal Anatomy Redefined
Dua, H. S., Faraj, L. A., Said, D. G., Gray, T., & Lowe, J. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.01.018 · Cited by 471
Vesicular systems in ocular drug delivery: an overview
Kaur, I. P., Garg, A., Singla, A. K., & Aggarwal, D. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.09.016 · Cited by 450
Mannermaa, E., Vellonen, K.-S., & Urtti, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.024 · Cited by 349
Recent advances in ocular drug delivery
Achouri, D., Alhanout, K., Piccerelle, P., & Andrieu, V. (2013) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2012.736515 · Cited by 335
Ghate, D., & Edelhauser, H. F. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.2.275 · Cited by 329
Ocular novel drug delivery: impacts of membranes and barriers
Barar, J., Javadzadeh, A. R., & Omidi, Y. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.5.567 · Cited by 308
Minimizing systemic absorption of topically administered ophthalmic drugs
Urtti, A., & Salminen, L. (1993) · Survey of Ophthalmology · doi:10.1016/0039-6257(93)90141-s · Cited by 265
Edelhauser, H. F., Rowe-Rendleman, C. L., Robinson, M. R., Dawson, D. G., Chader, G. J., Grossniklaus, H. E., Rittenhouse, K. D., Wilson, C. G., Weber, D. A., Kuppermann, B. D., et al. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5392 · Cited by 262
Periocular routes for retinal drug delivery
Raghava, S., Hammond, M., & Kompella, U. B. (2004) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.1.1.99 · Cited by 257
Almeida, H., Amaral, M. H., Lobão, P., & Lobo, J. M. S. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.001 · Cited by 257
del Amo, E. M., & Urtti, A. (2015) · Experimental Eye Research · doi:10.1016/j.exer.2015.05.003 · Cited by 231
Drolet, D. W., Nelson, J., Tucker, C. E., Zack, P. M., Nixon, K., Bolin, R., Judkins, M. B., Farmer, J. A., Wolf, J. L., Gill, S. C., et al. (2000) · Pharmaceutical Research · doi:10.1023/a:1007657109012 · Cited by 206
Xu, L., Lu, T., Tuomi, L., Jumbe, N., Lu, J., Eppler, S., Kuebler, P., Damico-Beyer, L. A., & Joshi, A. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-10260 · Cited by 201
Drug metabolism and pharmacokinetics
Benedetti, M. S., Whomsley, R., Poggesi, I., Cawello, W., Mathy, F.-X., Delporte, M.-L., Papeleu, P., & Watelet, J.-B. (2009) · Drug Metabolism Reviews · doi:10.1080/10837450902891295 · Cited by 201
Tucker, C. E., Chen, L.-S., Judkins, M. B., Farmer, J. A., Gill, S. C., & Drolet, D. W. (1999) · Journal of Chromatography B: Biomedical Sciences and Applications · doi:10.1016/s0378-4347(99)00285-6 · Cited by 176
Review: Practical Issues in Intravitreal Drug Delivery
Maurice, D. M. (2001) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/108076801753162807 · Cited by 153
del Amo, E. M., Vellonen, K., Kidron, H., & Urtti, A. O. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.01.003 · Cited by 148
Ocular Drug Delivery; Impact of in vitro Cell Culture Models.
Barar, J., Asadi, M., Mortazavi‐Tabatabaei, S. A., & Omidi, Y. (2009) · PubMed Central · Cited by 135
Clinical pharmacokinetics of the eye. Proctor lecture.
Mishima, S. (1981) · PubMed · Cited by 133
Di Tommaso, C., Bourges, J.-L., Valamanesh, F., Trubitsyn, G., Torriglia, A., Jeanny, J.-C., Behar-Cohen, F., Gurny, R., & Möller, M. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.02.014 · Cited by 128
Undefined role of mucus as a barrier in ocular drug delivery
Ruponen, M., & Urtti, A. O. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.02.032 · Cited by 112
INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA: Pharmacokinetic Considerations
Yang, Y. C., Bailey, C., Loewenstein, A., & Massin, P. (2015) · Retina · doi:10.1097/iae.0000000000000726 · Cited by 107
Anand, B. S., & Mitra, A. K. (2002) · Pharmaceutical Research · doi:10.1023/a:1019806411610 · Cited by 105
Self-citationTreatment of chronic dry eye: focus on cyclosporine
Kymionis, G. D. (2008) · Clinical ophthalmology · doi:10.2147/opth.s1409 · Cited by 94
Relevance of Drug-Melanin Interactions to Ocular Pharmacology and Toxicology
SALAZAR-BOOKAMAN, M. M., Wainer, I. W., & Patil, P. N. (1994) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.1994.10.217 · Cited by 86
Dey, S., Gunda, S., & Mitra, A. K. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.069583 · Cited by 85
Self-citationHayden, B. C., Jockovich, M. E., Murray, T. G., Voigt, M., Milne, P. J., Kralinger, M. T., Feuer, W. J., Hernandez, E., & Parel, J.-M. A. (2004) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-0228 · Cited by 84
Ocular Pharmacokinetics and Safety of Ciclosporin, a Novel Topical Treatment for Dry Eye
Tang-Liu, D. D.-S., & Acheampong, A. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544030-00003 · Cited by 79
The PK-Eye: A Novel In Vitro Ocular Flow Model for Use in Preclinical Drug Development
Awwad, S., Lockwood, A., Brocchini, S., & Khaw, P. T. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24480 · Cited by 78
Ocular drug delivery – a look towards nanobioadhesives
du Toit, L. C., Pillay, V., Choonara, Y. E., Govender, T., & Carmichael, T. R. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.542142 · Cited by 76
Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation
Schopf, L. R., Enlow, E., Popov, A., Bourassa, J. L., & Chen, H. (2014) · Ophthalmology and Therapy · doi:10.1007/s40123-014-0021-z · Cited by 70
Majumdar, S., Nashed, Y. E., Patel, K., Jain, R., Itahashi, M., Neumann, D. M., Hill, J. M., & Mitra, A. K. (2005) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2005.21.463 · Cited by 68
Self-citationCurrent prodrug strategies via membrane transporters/receptors
Anand, B. S., Dey, S., & Mitra, A. K. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.6.607 · Cited by 65
Self-citationJain-Vakkalagadda, B., Pal, D., Gunda, S., Nashed, Y. E., Ganapathy, V., & Mitra, A. K. (2004) · Molecular Pharmaceutics · doi:10.1021/mp0499499 · Cited by 57
Self-citationKatragadda, S., Talluri, R. S., & Mitra, A. K. (2006) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2006.22.110 · Cited by 54
Self-citationGunda, S., Hariharan, S., & Mitra, A. K. (2006) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2006.22.465 · Cited by 52
Self-citationJanoria, K. G., Boddu, S. H. S., Wang, Z., Paturi, D., Samanta, S., Pal, D., & Mitra, A. K. (2009) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2008.0040 · Cited by 51
Self-citationKatragadda, S., Gunda, S., Hariharan, S., & Mitra, A. K. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.03.015 · Cited by 50
Self-citationPrediction of Ocular Drug Distribution from Systemic Blood Circulation
Vellonen, K., Soini, E.-M., del Amo, E. M., & Urtti, A. O. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00729 · Cited by 49
Ocular Drug Distribution After Topical Administration: Population Pharmacokinetic Model in Rabbits
Djebli, N., Khier, S., Griguer, F., Coutant, A.-L., Tavernier, A., Fabre, G., Leriche, C., & Fabre, D. (2016) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-016-0319-4 · Cited by 49
Novack, G. D., & Robin, A. L. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.634 · Cited by 48
Majumdar, S., Hingorani, T., Srirangam, R., Gadepalli, R. S., Rimoldi, J. M., & Repka, M. A. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9730-0 · Cited by 46
Pharmacokinetics and safety of intravitreally delivered etanercept
Fauser, S., Kalbacher, H., Alteheld, N., Koizumi, K., Krohne, T. U., & Joussen, A. M. (2004) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-004-0895-x · Cited by 46
Stroke risk factors and subtypes in different age groups: A hospital-based study
Wu, C.-Y., Wu, C., Lee, J.-D., & Weng, H. (2010) · Neurology India · doi:10.4103/0028-3886.73747 · Cited by 46
Boddu, S. H. S., Gunda, S., Earla, R., & Mitra, A. K. (2010) · Bioanalysis · doi:10.4155/bio.10.2 · Cited by 46
Self-citationAnand, B. S., Katragadda, S., Nashed, Y. E., & Mitra, A. K. (2004) · Current Eye Research · doi:10.1080/02713680490504614 · Cited by 46
Self-citationSustained transscleral drug delivery
Barocas, V. H., & Balachandran, R. K. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.1.1 · Cited by 44
Shen, J., Durairaj, C., Lin, T., Liu, Y., & Burke, J. A. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-13650 · Cited by 40
Vadlapudi, A. D., Vadlapatla, R. K., Earla, R., Sirimulla, S., Bailey, J., Pal, D., & Mitra, A. K. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1059-7 · Cited by 38
Self-citationEvaluation of Sub-Tenon Triamcinolone Acetonide Injections in the Treatment of Scleritis
Johnson, K. S., & Chu, D. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.07.035 · Cited by 36
Kapanigowda, U. G., Sreeharsha, N., Ramaiah, B., & Boggarapu, P. R. (2015) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/s40199-015-0132-7 · Cited by 35
Hariharan, S., Minocha, M., Mishra, G. P., Pal, D., Krishna, R., & Mitra, A. K. (2009) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2009.0049 · Cited by 33
Self-citationKansara, V. S., Hao, Y., & Mitra, A. K. (2007) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2006.0150 · Cited by 31
Self-citationLe, K. N., Gibiansky, L. V., Good, J., Davancaze, T., Campagne, M. V. L., Loyet, K. M., Morimoto, A. M., Jin, J., Damico‐Beyer, L. A., & Hanley, W. D. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.227223 · Cited by 31
Transporter effects on cell permeability in drug delivery
Mandal, A., Agrahari, V., Khurana, V., Pal, D., & Mitra, A. K. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1214565 · Cited by 25
Self-citationWinter, U., Buitrago, E., Mena, H. A., Sole, M. J. D., Laurent, V. E., Negrotto, S., Francis, J. H., Arana, E., Sgroi, M., Croxatto, J. O., et al. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-16239 · Cited by 22
Liu, Y., Peng, Y., Lwin, N. C., Wong, T. T. L., Venkatraman, S. S., & Mehta, J. S. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-11466 · Cited by 20
Cholkar, K., Vadlapudi, A. D., Trinh, H. M., & Mitra, A. K. (2013) · Methods in pharmacology and toxicology · doi:10.1007/7653_2013_10 · Cited by 12
Self-citationAnecortave acetate in the treatment of age-related macular degeneration
Augustin, A. J. (2006) · Clinical Interventions in Aging · doi:10.2147/ciia.2006.1.3.237 · Cited by 11
Biology of ocular transporters: efflux and influx transporters in the eye
Dhananjay, P., Krishna, V., Dutt, V. A., & Mitra, A. (2013) · Elsevier eBooks · doi:10.1533/9781908818317.37 · Cited by 8
Self-citationTransporter–metabolism interplay in the eye
Barot, M., Patel, M., Kwatra, D., & Mitra, A. K. (2013) · Elsevier eBooks · doi:10.1533/9781908818317.229 · Cited by 7
Self-citation
Cited by
Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine
Sousa de Almeida, M., Susnik, E., Drasler, B., Taladriz-Blanco, P., Petri-Fink, A., & Rothen-Rutishauser, B. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01127d · Cited by 1,079
Advances and limitations of drug delivery systems formulated as eye drops
Jumelle, C., Gholizadeh, S., Annabi, N., & Dana, R. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.057 · Cited by 408
Nanotechnology-based ocular drug delivery systems: recent advances and future prospects
Li, S., Chen, L., & Fu, Y. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01992-2 · Cited by 277
Principles of pharmacology in the eye
Awwad, S., Mohamed Ahmed, A. H. A., Sharma, G., Heng, J. S., Khaw, P. T., Brocchini, S., & Lockwood, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14024 · Cited by 224
Zhao, X., Seah, I., Xue, K., Wong, W., Tan, Q. S. W., Ma, X., Lin, Q., Lim, J. Y. C., Liu, Z., Parikh, B. H., et al. (2022) · Advanced Materials · doi:10.1002/adma.202108360 · Cited by 84
Metadata
- Authors
- Agrahari, V., Mandal, A., Agrahari, V., Trinh, H. M., Joseph, M., Ray, A., Hadji, H., Mitra, R., Pal, D., & Mitra, A. K.
- Venue
- Drug Delivery and Translational Research
- Published
- 2016-10-31
- Volume
- 6
- Issue
- 6
- Pages
- 735-754
- ISSN
- 2190-393X (ISSN-L)
- 2190-3948
- OpenAlex
- W2539812081
- Cited by
- 462
- References
- 70
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.